Telix announced that it has entered into an exclusive commercial distribution agreement with Bologna-based Radius S.r.l. (Radius) for Telix’s prostate cancer investigational imaging product Illuccix® (Kit for the preparation of 68Ga-PSMA-11 injection) for the Italian market. This agreement builds on the support Radius has provided Telix in distributing 68Ga-PSMA-11 for magisterial use in Italy.
Under
the terms of the agreement, Radius will be the exclusive commercial distributor
of Illuccix® in Italy for a period of three years from the national approval
date. Radius is the market leader in the supply of gallium generators across
Italy, a position which enables Radius to provide a secure supply of the 68Ga
necessary for launching Illuccix®. Radius also has the advantage of being a
supplier and service provider for cyclotrons and radiotherapy suites across
Italy.
To
read more please visit:
Telix
and Radius Sign Italian Distribution Agreement for Prostate Cancer Imaging
Source: TELIX